Cipla Signs Exclusive Deal for Keytruda Biosimilar in US Market

MUMBAI, India — Cipla Limited announced on September 3, 2026, that its wholly-owned US subsidiary, InvaGen Pharmaceuticals Inc., has entered into an exclusive licensing and supply partnership with China-based Qilu Pharmaceutical. Under the agreement, Cipla USA will secure exclusive commercialization rights in the United States for QL2107, a biosimilar candidate to Merck’s blockbuster oncology therapy Keytruda (pembrolizumab). The partnership provides Cipla entry into the high-margin US oncology biologics sector ahead of Keytruda’s loss of exclusivity.

Terms of Agreement and Operational Responsibilities

Under the regulatory terms of the agreement, Qilu Pharmaceutical will remain responsible for the clinical development, regulatory filings, and manufacturing supply of QL2107. Cipla’s North American commercial arm will lead market distribution, sales, and commercial rollout upon receiving approval from the US Food and Drug Administration (USFDA).

• Commercializing Entity: Cipla USA / InvaGen Pharmaceuticals Inc.

• Development & Supply Entity: Qilu Pharmaceutical Co., Ltd.

• Asset Name: QL2107 (Pembrolizumab Biosimilar)

• Reference Product: Keytruda® (Merck & Co., Inc.)

• Target Territory: United States

• Qilu Scope: R&D, Phase 3 Clinical Trials, Supply

• Cipla Scope: USFDA Commercialization & Sales

Clinical Status and Market Context

Keytruda (pembrolizumab) is currently the world's top-selling anti-PD-1 immunotherapy, indicated for various oncology conditions, including non-small cell lung cancer, melanoma, and solid tumors. Qilu Pharmaceutical is actively advancing QL2107 through global clinical evaluation, including Phase 3 pharmacokinetic equivalence trials comparing QL2107 to Keytruda.

The strategic arrangement allows Cipla to build defensibility against generic erosion in its core portfolio without incurring full research and development capital costs.

Official Sources Section

According to official corporate press releases and regulatory disclosures filed by Cipla Limited with the stock exchanges on September 3, 2026.

Quote Section

According to official executive announcements released by the partnering companies:

"This strategic collaboration with Qilu Pharmaceutical for QL2107 aligns with our commitment to expanding patient access to complex, high-value biologic treatments in the US. By combining Qilu's clinical and manufacturing capabilities with Cipla’s commercial engine, we strengthen our North American specialty pipeline."

Why It Matters

• For Cancer Patients: Expands future availability of lower-cost biosimilar alternatives to Keytruda in the US.

• For Cipla Shareholders: Offers capital-efficient entry into the multi-billion dollar US oncology market without heavy R&D expenditure.

• For the Biopharma Industry: Reflects accelerating cross-border licensing partnerships aiming to capture upcoming loss-of-exclusivity windows for major biologic drugs.

Key Facts at a Glance

• Partnership Asset: QL2107, a biosimilar candidate to Keytruda (pembrolizumab).

• Commercial Territory: Exclusive distribution rights reserved for the United States market.

• Division of Roles: Qilu handles clinical development and supply; Cipla USA manages commercialization.

• Execution Entity: Cipla’s wholly-owned US arm, InvaGen Pharmaceuticals Inc.

Frequently Asked Questions

What is QL2107?

QL2107 is an investigational biosimilar candidate developed by Qilu Pharmaceutical that references Merck’s cancer drug Keytruda (pembrolizumab).

What role will Cipla play in this agreement?

Cipla, through its US arm InvaGen Pharmaceuticals, holds exclusive rights to commercialize, distribute, and market QL2107 in the United States following regulatory approval.

Who will manufacture and develop the biosimilar drug?

Qilu Pharmaceutical remains responsible for conducting clinical trials, securing regulatory approval, and managing commercial manufacturing supply.

Source: Official regulatory disclosures and media announcements issued by Cipla Limited and Qilu Pharmaceutical Co., Ltd.